Get the Stockscreener App
0.88
0.23%
-0.0058
Renovorx Inc stock is traded at $0.88, with a volume of 12,570.
It is down -0.23% in the last 24 hours and up +7.78% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.8858
Open:
$0.8768
24h Volume:
12,570
Relative Volume:
0.03
Market Cap:
$40.05M
Revenue:
$1.12M
Net Income/Loss:
$-11.17M
P/E Ratio:
-2.7839
EPS:
-0.3161
Net Cash Flow:
$-10.98M
1W Performance:
+2.77%
1M Performance:
+7.78%
6M Performance:
+4.88%
1Y Performance:
-32.53%
1-Day Range:
$0.8701
$0.8918
1-Week Range:
$0.8407
$0.9032
52-Week Range:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.888 | 39.95M | 1.12M | -11.17M | -10.98M | -0.3161 |
VRTX
Vertex Pharmaceuticals Inc
|
449.73 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.46 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.90 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.34 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.46 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - The Manila Times
Targeted artery chemo saw 52% tumor activity drop in pancreatic cancer case - Stock Titan
RenovoRx (RNXT) Q1 2026 Earnings: EPS Falls Short of Estimates as Pre-Revenue Biotech Advances Clinical PipelineGuidance Update - newsline.com
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Oncology Firm Advances Clinical PipelineEarnings Whisper Number - newsline.com
RenovoRx Inc. (RNXT) Holds Steady Near Support as Investors Eye ResistanceInstitutional Flow Picks - newsline.com
RNXT Q1 2026 Earnings: EPS Miss Widens Losses as Stock Declines 10.6%Post-Earnings Drift - newsline.com
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - Investing News Network
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Clinical PipelinePre-Announcement Alert - newsline.com
RNXT Maintains Buy Rating by Ascendiant Capital -- Price Target Raised to $14.00 - GuruFocus
New chemotherapy delivery method scores FDA orphan drug status - Rare Cancer News
RNXT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances TrialsEarnings Preview - The Legal Advocate
RenovoRx Inc. (RNXT) Moves Higher by 6.2% as Shares Approach Resistance at $1.04Volatility Term Structure - The Legal Advocate
RenovoRx (RNXT) Advances 6.2% as Momentum Builds Toward ResistanceCall Spread Alert - The Legal Advocate
RenovoRx receives FDA orphan drug designation for oxaliplatin - Investing.com UK
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - Investing News Network
RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com - Investing.com Australia
RenovoRx gets FDA orphan drug designation for oxaliplatin to treat pancreatic cancer - marketscreener.com
RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer - TradingView
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer - Stock Titan
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting - Investing News Network
RenovoRx reports pharmacokinetic data from pancreatic trial By Investing.com - Investing.com Nigeria
RenovoRx reports pharmacokinetic data from pancreatic trial - Investing.com
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - The Manila Times
Pancreatic cancer study tests drug delivery that may cut side effects - Stock Titan
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEPS Growth Report - newsline.com
RenovoRx Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineEPS Estimate Trend - Newser
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss; Stock Holds SteadyCrowd Stock Picks - Newser
RenovoRx Q1 2026 Earnings: EPS Miss as Pre-Revenue Biotech Continues Clinical DevelopmentNet Income Trends - Newser
RenovoRx Inc. (RNXT) Hovers Near Support as Thin Trading PersistsExpert Momentum Signals - Newser
RenovoRx (RNXT) Slides to $0.88, Nearing Critical SupportRetail Driven Moves - Newser
RenovoRx CFO Mark Voll buys $19,690 in common stock By Investing.com - Investing.com Canada
RenovoRx CFO Mark Voll buys $19,690 in common stock - Investing.com India
RenovoRx (RNXT) Q1 2026 Results Trail Estimates: A Deeper LookGuidance Accuracy Score - Newser
RenovoRx (RNXT) CFO adds 25,000 shares, lifting direct stake to 142,380 - Stock Titan
RNXT: Targeted chemo delivery platform drives revenue growth and nears key clinical milestones - TradingView
RNXT: Targeted drug delivery platform drives revenue growth and nears key clinical milestones - TradingView
RenovoRx (RNXT) Q1 2026 Results Miss Estimates — EPS $-0.09 vs $-0.08Working Capital - Newser
RenovoRx Earnings Call Signals Commercial Inflection - TipRanks
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th - Investing News Network
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Jan 21 '26 |
Buy |
1.00 |
10,000 |
9,975 |
798,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 31 '25 |
Buy |
0.86 |
9,795 |
8,424 |
788,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):